
    
      Approximately 75 patients will be randomized in a 1:2:2 ratio to 3 arms:

      Arm 1: placebo+ACT group (15 patients)

      Arm 2: 5 ALA/SFC+Placebo+ACT twice daily (BID) (30 patients)

      Arm 3: 5-ALA/SFC+Placebo+ACT once daily (QD) (30 patients)

      The study duration will be a maximum of 98 days with treatment period of 7 days and follow-up
      period of 91 days.
    
  